HALO logo
halo search icon
CYAD
Celyad Oncology SA

CYAD · Celyad Oncology SA

0.24

EUR
-0.01 (-5.41%)
23/06/2026 12:00:00 AM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Euro10.97M

PE

8.80

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 23/06/2026 12:00:00 AM

Price Chart

Description

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

  • All-Companies
  • HALO 100
  • HALO All
  • HALO Small
  • Near Support

Key Fundamentals

EPS 3 yr Growth

-101.10%

EBITDA Margin

NaN%

Operating Cashflow

-€7m

Free Cash Flow Return

-372.00%

ROIC

44.70%

Interest Coverage

-109.50

Quick Ratio

1.90

Performance

52 weeks range

Low 0.16 - 0.65

Trade Value (12mth)

US$4,598.00

1 week

-7.2%

1 month

-18.06%

YTD

33.88%

1 year

-34.84%

All time high

70.95

Additional Data

Shares Outstanding (Fully Diluted)

41m

HALO Sector

Healthcare

Next Company Report Date

25-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

EUR

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Very Weak

Momentum

Price

Neutral

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

No announcements available.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
The current share price of Celyad Oncology SA (CYAD:BRU) is EUR€0.24.
2
What is the 52-week high share price for Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
The 52-week high share price for Celyad Oncology SA (CYAD:BRU) is EUR€0.65.
3
What is the 52-week low share price for Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
The 52-week low share price for Celyad Oncology SA (CYAD:BRU) is EUR€0.16.
4
What is the dividend yield for Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
Celyad Oncology SA (CYAD:BRU) does not pay a dividend.
5
What was Celyad Oncology SA (CYAD:BRU) last dividend payment?
Halo FAQ
Celyad Oncology SA (CYAD:BRU) does not pay a dividend.
6
What is the franking level for Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
Celyad Oncology SA (CYAD:BRU) has a franking level of 0.00%.
7
In which sector is Celyad Oncology SA (CYAD:BRU) classified?
Halo FAQ
Celyad Oncology SA (CYAD:BRU) is classified in the Healthcare.
8
What is the price-to-earnings (P/E) ratio for Celyad Oncology SA (CYAD:BRU)?
Halo FAQ
The current P/E ratio for Celyad Oncology SA (CYAD:BRU) is 8.80.